iCAD Exhibiting New Updates and Enhanced Xoft Platform at ASTRO Including Single-Fraction IORT Solution for the Treatment of Early-Stage Breast Cancer
Enhanced x-ray
source technology and full suite of Xoft eBx applicators to be showcased, including
those for emerging applications in prostate, brain, and rectal cancers
NASHUA, N.H. and CHICAGO – September 16, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions,
today announced the Company will showcase its latest advancements for the Xoft®
Axxent® Electronic Brachytherapy (eBx®) System®, including new and updated
x-ray sources and the full suite of applicators for existing and emerging
applications in the Xoft exhibition booth (#4205) at the American Society for
Radiation Oncology (ASTRO) Annual Meeting in Chicago at McCormick Place West from
September 15-18, 2019. iCAD will also be concurrently exhibiting at the Society
for Radiation Oncology Administrators (SROA) Annual Meeting at the Hilton
Chicago from September 15-18, 2019.
“The Xoft System is a transformative radiation
treatment option that offers a targeted, single-fraction therapy for early-stage
breast cancer, along with the added versatility and cross-functionality to
treat other types of cancers, such as nonmelanoma skin cancers and
gynecological cancers,” according to Gary Proulx, MD, medical director
and radiation oncologist at Exeter Hospital and featured expert speaker at
iCAD’s “Evening of eBx” event scheduled to take place during the meeting. “As cancer treatment becomes increasingly
targeted and value-based, iCAD’s Xoft System continues to be an established
trailblazer in this revolutionary trend towards more personalized cancer
treatment.”
Leading
experts will be available in the Xoft booth throughout ASTRO and SROA to
discuss their clinical experience using the technology across various cancer
types. The Xoft System will be available for demonstration in the booth at
ASTRO and new and updated advancements will be unveiled, including those
highlighted below:
- New applicators for minimally-invasive robotic
surgery, including prostate, as well as an advanced prototype for early-stage
rectal cancers - Extended-length balloon applicators, now
available in 25 mm and 50 mm lengths, which offer added versatility and the
potential for additional applications for Xoft eBx in different areas of the
body - Extended-life x-ray sources, featuring a
ten-fold increase in treatment times, which offer time-saving benefits for
clinicians and enhance efficiency - The full suite of currently-available eBx applicators,
including those with established data for early-stage breast cancer,
gynecological cancers, nonmelanoma skin cancers, and most recently, brain
cancers - World-class treatment planning programs, developed
for both the Xoft controller and general intraoperative radiation therapy
(IORT) with the Xoft System
For
early-stage breast cancer patients, IORT with the Xoft System allows appropriately
selected patients to potentially replace six to eight weeks of post-operative
external beam radiation therapy (EBRT) with a single-fraction of radiation that
can last as little as eight minutes. It uses a
miniaturized x-ray source to deliver one precise, concentrated dose of
radiation directly to the tumor site, while minimizing risk of damage to
healthy tissue in nearby areas of the body.
“We may be approaching a significant paradigm shift in the way
clinicians treat cancer, especially with a likely decision on the Radiation
Oncology Alternative Payment Model (RO-APM) anticipated in the months ahead,”
said Michael Klein, Chairman and CEO of iCAD. “As a single-fraction treatment
therapy for early-stage breast cancer, Xoft IORT is a viable and verified
treatment option that appears well-aligned with the core elements of the
proposed model. The Company is poised to transform patient experiences and
outcomes in the years ahead as a platform technology across multiple cancer
indications.”
A growing body of evidence continues to support the Xoft System
across multiple cancer types. At ASTRO, findings from a Vanderbilt University
School of Medicine study supporting Xoft IORT for early-stage breast cancer will
be presented on Sunday, September 15 at 1:15 pm CT in the Breast Cancer Track.
iCAD will also host “An Evening of eBx” cocktail
reception on Monday, September 16, at the
Marriott Marquis Chicago at 6 pm CT. The event will feature clinical experts
who will discuss the latest research and emerging applications for eBx and IORT
with the Xoft System.
The Xoft System is FDA-cleared, CE marked, and
licensed in a growing number of countries for the treatment of cancer anywhere
in the body, including early-stage breast cancer, nonmelanoma skin cancer, and
gynecological cancers. For more information, please visit www.xoftinc.com.
About iCAD, Inc.
Headquartered in Nashua,
NH, iCAD is a global medical technology leader providing innovative cancer
detection and therapy solutions. For more information, visit www.icadmed.com.
“Safe Harbor” Statement under the Private Securities
Litigation Reform Act of 1995
Certain statements contained in this News Release constitute
“forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements involve a number
of known and unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of the Company to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements. Such factors include, but are not
limited, to the Company’s ability to defend itself in litigation matters, to
achieve business and strategic objectives, the risks of uncertainty of patent
protection, the impact of supply and manufacturing constraints or difficulties,
uncertainty of future sales levels, protection of patents and other proprietary
rights, the impact of supply and manufacturing constraints or difficulties,
product market acceptance, possible technological obsolescence of products,
increased competition, litigation and/or government regulation, changes in
Medicare or other reimbursement policies, risks relating to our existing and
future debt obligations, competitive factors, the effects of a decline in the
economy or markets served by the Company; and other risks detailed in the
Company’s filings with the Securities and Exchange Commission. The words
“believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,”
“anticipate,” “likely,” “seek,” and similar expressions identify
forward-looking statements. Readers are cautioned not to place undue reliance
on those forward-looking statements, which speak only as of the date the
statement was made. The Company is under no obligation to provide any updates
to any information contained in this release. For additional disclosure
regarding these and other risks faced by iCAD, please see the disclosure
contained in our public filings with the Securities and Exchange Commission,
available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website
at http://www.sec.gov.
Contacts:
Media Inquiries:
Jessica Burns, iCAD
+1 (201) 423-4492
Investor Relations:
Jeremy Feffer, LifeSci Advisors
+1 (212) 915-2568
###